Enalaprilat Inhibits Zinc-Dependent Oligomerization of Metal-Binding Domain of Amyloid-beta Isoforms and Protects Human Neuroblastoma Cells from Toxic Action of these Isoforms

[1]  Ying-Zi Qi,et al.  Long non-coding RNA and mRNA analysis of Ang II-induced neuronal dysfunction , 2019, Molecular Biology Reports.

[2]  G. Aliev,et al.  Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention , 2017, Pharmacological research.

[3]  A. Makarov,et al.  A Binuclear Zinc Interaction Fold Discovered in the Homodimer of Alzheimer's Amyloid-β Fragment with Taiwanese Mutation D7H. , 2017, Angewandte Chemie.

[4]  S. Bachurin,et al.  Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends , 2017, Medicinal research reviews.

[5]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2017 , 2017, Alzheimer's & dementia.

[6]  A. Makarov,et al.  Heat-shock protein HSP70 reduces the secretion of TNFα by neuroblastoma cells and human monocytes induced with beta-amyloid peptides , 2016, Molecular Biology.

[7]  A. Makarov,et al.  Amyloid-β containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease , 2016 .

[8]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[9]  A. Makarov,et al.  Zinc-induced heterodimer formation between metal-binding domains of intact and naturally modified amyloid-beta species: implication to amyloid seeding in Alzheimer’s disease? , 2016, Journal of biomolecular structure & dynamics.

[10]  A. Makarov,et al.  Interplay of histidine residues of the Alzheimer’s disease Aβ peptide governs its Zn-induced oligomerization , 2016, Scientific Reports.

[11]  A. Makarov,et al.  Intracerebral Injection of Metal-Binding Domain of Aβ Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice , 2016, Neurotoxicity Research.

[12]  A. Makarov,et al.  HSP70 protects human neuroblastoma cells from apoptosis and oxidative stress induced by amyloid peptide isoAsp7-Aβ(1–42) , 2015, Cell Death and Disease.

[13]  A. Makarov,et al.  Roles of zinc ions and structural polymorphism of β-amyloid in the development of Alzheimer’s disease , 2015, Molecular Biology.

[14]  A. Makarov,et al.  [The role of zinc ions and structural polymorphism of β-amyloid in the Alzheimer's disease initiation]. , 2015, Molekuliarnaia biologiia.

[15]  W. Klein,et al.  Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis , 2015, Acta Neuropathologica.

[16]  P. Tsvetkov,et al.  Isomerization of Asp7 leads to increased toxic effect of amyloid-β42 on human neuronal cells , 2013, Cell Death and Disease.

[17]  C. Masters,et al.  Structural studies of the tethered N‐terminus of the Alzheimer's disease amyloid‐β peptide , 2013, Proteins.

[18]  Pedro Rosa-Neto,et al.  Performance testing of a fully automated, Chemiluminescent, beta-amyloid 42 assay , 2013, Alzheimer's & Dementia.

[19]  A. Makarov,et al.  ESI-MS identification of the minimal zinc-binding center in natural isoforms of β-amyloid domain 1–16 , 2013, Molecular Biology.

[20]  P. Tsvetkov,et al.  Peripherally Applied Synthetic Peptide isoAsp7-Aβ(1-42) Triggers Cerebral β-Amyloidosis , 2013, Neurotoxicity Research.

[21]  A. Makarov,et al.  [Identification of the minimal zinc-binding center in natural isoforms of amyloid-beta domain 1-16 using ESI-MS]. , 2013, Molekuliarnaia biologiia.

[22]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[23]  P. Tsvetkov,et al.  Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology , 2012, Molecular Biology.

[24]  P. Tsvetkov,et al.  NMR solution structure of rat aβ(1-16): toward understanding the mechanism of rats' resistance to Alzheimer's disease. , 2012, Biophysical journal.

[25]  Blaine R. Roberts,et al.  The role of metallobiology and amyloid‐β peptides in Alzheimer’s disease , 2012, Journal of neurochemistry.

[26]  V. Buchman,et al.  Dimebon Slows Progression of Proteinopathy in γ-Synuclein Transgenic Mice , 2011, Neurotoxicity Research.

[27]  I. Grundke‐Iqbal,et al.  Opportunities and challenges in developing Alzheimer disease therapeutics , 2011, Acta Neuropathologica.

[28]  K. Kataoka,et al.  Perindopril, a centrally active angiotensin‐converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  P. Tsvetkov,et al.  Zinc-induced dimerization of the amyloid-β metal-binding domain 1-16 is mediated by residues 11-14. , 2011, Molecular bioSystems.

[30]  Alexander A. Makarov,et al.  Minimal Zn(2+) binding site of amyloid-β. , 2010, Biophysical journal.

[31]  N. Ferguson,et al.  Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils , 2010, The Journal of Neuroscience.

[32]  A. Makarov,et al.  Effect of isomerization of aspartate-7 on the binding of copper (II) ion by the β-amyloid peptide , 2009, Biofizika.

[33]  R. Metherate,et al.  A Role for Synaptic Zinc in Activity-Dependent Aβ Oligomer Formation and Accumulation at Excitatory Synapses , 2009, The Journal of Neuroscience.

[34]  P. Tsvetkov,et al.  Isomerization of the Asp7 Residue Results in Zinc‐Induced Oligomerization of Alzheimer’s Disease Amyloid β(1–16) Peptide , 2008, Chembiochem : a European journal of chemical biology.

[35]  A. Makarov,et al.  The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2008, Rapid communications in mass spectrometry : RCM.

[36]  A. Mazur,et al.  Structural Changes of Region 1-16 of the Alzheimer Disease Amyloid β-Peptide upon Zinc Binding and in Vitro Aging* , 2006, Journal of Biological Chemistry.

[37]  Andrei Surguchov,et al.  Protein Aggregation in Retinal Cells and Approaches to Cell Protection , 2005, Cellular and Molecular Neurobiology.

[38]  Georgios A Spyroulias,et al.  Structure-function discrimination of the N- and C- catalytic domains of human angiotensin-converting enzyme: implications for Cl- activation and peptide hydrolysis mechanisms. , 2003, Protein engineering.

[39]  J. Tabet,et al.  Zinc binding properties of the amyloid fragment Aβ(1–16) studied by electrospray-ionization mass spectrometry , 2003 .

[40]  R. Natesh,et al.  Crystal structure of the human angiotensin-converting enzyme–lisinopril complex , 2003, Nature.

[41]  G. H. Hoa,et al.  Zinc binding to Alzheimer's Abeta(1-16) peptide results in stable soluble complex. , 2001, Biochemical and biophysical research communications.

[42]  R. Heel,et al.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. , 1986, Drugs.

[43]  Makarov Aa,et al.  [New biomarkers and drug targets for diagnosis and therapy of Alzheimer's disease (molecular determinants of zinc-dependent oligomerization of Β-amyloid)]. , 2015 .

[44]  V. Buchman,et al.  Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. , 2013, Journal of Alzheimer's disease : JAD.